MétaCan
Menu
Back to cohort
Record W2954298172 · doi:10.1016/j.euf.2019.06.002

The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

2019· review· en· W2954298172 on OpenAlexaff
Rohann Correa, Alexander V. Louie, Nicholas G. Zaorsky, Eric J. Lehrer, Rodney J. Ellis, Lee Ponsky, Irving Kaplan, Anand Mahadevan, William Chu, Anand Swaminath, Raquibul Hannan, Hiroshi Onishi, Bin S. Teh, Alexander Muacevic, Simon S. Lo, Michael Staehler, Shankar Siva

Bibliographic record

VenueEuropean Urology Focus · 2019
Typereview
Languageen
FieldMedicine
TopicRenal cell carcinoma treatment
Canadian institutionsHealth Sciences CentreCancer Care OntarioMcMaster UniversityUniversity of TorontoJuravinski Cancer CentreSunnybrook Health Science Centre
FundersAccurayElektaVarian Medical Systems
KeywordsMedicineAblative caseRenal cell carcinomaMeta-analysisRadiation therapySystematic reviewOncologyStereotactic radiotherapyMEDLINERadiosurgeryInternal medicine

Abstract

fetched live from OpenAlex

Context Stereotactic ablative radiotherapy (SABR) is an emerging treatment option for primary renal cell carcinoma (RCC). Objective To systematically review the literature on SABR for primary RCC and perform a meta-analysis evaluating local control (LC), toxicity, and renal function. Evidence acquisition A PROSPERO-registered (#115573), Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA)-based systematic review of the literature was conducted (1995–2019). Studies of SABR targeting primary RCC tumors were included, while those targeting only metastases were excluded. The primary outcome was LC defined as tumor size reduction and/or absence of local progression. Secondary outcomes included toxicity (Common Terminology Criteria for Adverse Events) and renal function (change in estimated glomerular filtration rate [eGFR]). Weighted random-effect meta-analyses using the DerSimonian and Laird method were conducted for primary and secondary outcomes. The I 2 statistic and Cochran's Q test were used to assess heterogeneity. Evidence synthesis From 2386 PubMed entries and 924 meeting abstracts, 26 studies were identified (11 prospective trials), including 383 tumors in 372 patients, most of whom were deemed inoperable. Weighted averages (ranges) of median follow-up, median age, and mean tumor size were 28.0 (5.8–79.2)mo, 70.4 (62–83)yr, and 4.6 (2.3–9.5)cm, respectively. RCC histology was confirmed in 78.9% of patients who underwent pretreatment biopsy. Dose fractionation varied, but 26Gy in one fraction and 40Gy in five fractions were most common. The random-effect estimates for LC, grade 3–4 toxicity, and post-SABR eGFR change were 97.2% (95% confidence interval [CI]: 93.9–99.5%, I 2 =20%), 1.5% (95% CI: 0–4.3%, I 2 =0%), and –7.7ml/min (95% CI: –12.5 to –2.8, I 2 =2%), respectively, and heterogeneity was minimal. Six patients with pre-existing renal dysfunction (2.9%) required dialysis. Conclusions Renal SABR is locally effective and associated with low toxicity rates for primary RCC, despite treatment of larger tumors in older, mostly medically inoperable patients. Patient summary Stereotactic ablative radiotherapy is a high-precision, noninvasive radiation treatment requiring few outpatient visits, and represents a safe and effective management option for primary renal cell carcinoma.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.024
metaresearch head score (Gemma)0.047
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.024
Threshold uncertainty score0.124

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0240.047
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0170.038
Bibliometrics0.0080.008
Science and technology studies0.0010.001
Scholarly communication0.0040.002
Open science0.0020.001
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.306
Teacher spread0.254 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations134
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Urology FocusSame topicRenal cell carcinoma treatmentFrench-language works237,207